1y return+181.0%S&P 500 +20.9%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since December 31, 2024: $264 against $127 in the S&P 500.2
Boxer Capital Management, LLCS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| TNGXTango Therapeutics Inc | $340.0M | 25.6% | |
| RVMDRevolution Medicines Inc | $93.6M | 7.1% | |
| ABVXAbivax Sa | $80.6M | 6.1% | +202.5% |
| Uniqure NvCUSIP N90064101 | $69.2M | 5.2% | +127.1% |
| KODKodiak Sciences Inc | $57.6M | 4.3% | +8.6% |
| KYMRKymera Therapeutics Inc | $49.2M | 3.7% | +30.4% |
| DFTXDefinium Therapeutics Inc | $47.0M | 3.5% | +66.8% |
| REPLReplimune Group Inc | $44.1M | 3.3% | +239.0% |
| CELCCelcuity Inc | $43.6M | 3.3% | +85.1% |
| QTTBQ32 Bio Inc | $40.1M | 3.0% | New |
| CAPRCapricor Therapeutics Inc | $33.6M | 2.5% | +136.5% |
| PGENPrecigen Inc | $29.4M | 2.2% | +47.1% |
| CORTCorcept Therapeutics Inc | $29.2M | 2.2% | +34.2% |
| SRZNSurrozen Inc. | $27.0M | 2.0% | +44.3% |
| PTGXProtagonist Therapeutics Inc | $20.8M | 1.6% | |
| VIRVir Biotechnology Inc | $19.0M | 1.4% | |
| PCVXVaxcyte Inc | $18.9M | 1.4% | |
| Urogen Pharma LtdCUSIP M96088105 | $18.4M | 1.4% | |
| CRVSCorvus Pharmaceuticals Inc | $16.4M | 1.2% | |
| PTCTPtc Therapeutics Inc | $16.3M | 1.2% | |
| PRAXPraxis Precision Medicines I | $15.6M | 1.2% | |
| AMLXAmylyx Pharmaceuticals Inc | $14.4M | 1.1% | |
| OCULOcular Therapeutix Inc | $12.8M | 1.0% | +271.4% |
| IRDOpus Genetics Inc | $11.6M | 0.9% | +25.1% |
| PALIPalisade Bio Inc | $10.0M | 0.8% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| AMLXAmylyx Pharmaceuticals Inc | December 31, 2024 | +375.1% | $14.4M |
| RVMDRevolution Medicines Inc | December 31, 2024 | +328.2% | $93.6M |
| Apogee Therapeutics IncCUSIP 03770N101 | September 30, 2025 | +234.1% | $9.3M |
| KYMRKymera Therapeutics Inc | December 31, 2024 | +185.0% | $49.2M |
| MLTXMoonlake Immunotherapeutics | September 30, 2025 | +171.5% | $5.4M |
| Urogen Pharma LtdCUSIP M96088105 | June 30, 2025 | +168.6% | $18.4M |
| DFTXDefinium Therapeutics Inc | March 31, 2026 | +148.9% | $47.0M |
| PTGXProtagonist Therapeutics Inc | June 30, 2025 | +121.8% | $20.8M |
| CORTCorcept Therapeutics Inc | March 31, 2026 | +115.7% | $29.2M |
| CELCCelcuity Inc | September 30, 2025 | +111.8% | $43.6M |
Sold off last quarter
- Terns Pharmaceuticals IncCUSIP 880881107 was $19.8M
- Soleno Therapeutics IncCUSIP 834203309 was $6.7M
- Kalvista Pharmaceuticals IncCUSIP 483497103 was $411K
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +34.0% | +14.8% |
| March 31, 2026 | +36.1% | −4.6% |
| December 31, 2025 | +12.7% | +2.4% |
| September 30, 2025 | +36.7% | +7.8% |
| June 30, 2025 | +9.1% | +10.5% |
| March 31, 2025 | −13.8% | −4.6% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Boxer Capital Management, LLC Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=2018299&type=13F-HR&dateb=&owner=include&count=40CIK 2018299
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/2018299/000121390026090024/Filed August 14, 2026 · accession 0001213900-26-090024